Valneva Reports Q1 2022 Results and Provides Corporate Updates
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
📰 Human Use News
Page 142 - Human Use News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Human Use. Real-time updates on events, politics, business and more.
Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
– Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners – –...
Source: prnewswire.com
EC approves Novartis' Kymriah for follicular lymphoma in adults
The EC has granted approval for Novartis’ CAR-T cell therapy, Kymriah, to treat adults with relapsed or refractory follicular lymphoma.
Novarti Kymriah European Medicines Agency European Commission Drug Administration Novartis Innovative Medicines International Committee For Medicinal Products Human Use
Source: pharmaceutical-technology.com
EC approval for post-steroid graft-versus-host treatment
Jakavi treats a potentially life-threatening condition which often effects transplant patients - News - PharmaTimes
Robert Zeiser Innovative Medicines International Committee For Medicinal Products Human University Hospital Freiburg European Commission Department Of Haematology
Source: pharmatimes.com
Novartis Kymriah receives EC approval for lymphoma treatment
Approval for Kymriah follows a positive CHMP opinion and is applicable to all 27 EU member states - News - PharmaTimes
Catherine Thieblemont European Commission Committee For Medicinal Products Human Use Medicinal Products Human Use Marie France Tschudin
Source: pharmatimes.com
Novartis Nabs European Approval for Kymriah in Follicular Lymphoma
The European Commission approved the autologous CAR T-cell therapy for relapsed or refractory follicular lymphoma patients after two or more prior treatments.
Bristol Myers Squibb European Commission On Drug Administration For Kymriah European Commission European Medicines Agency Medicinal Products
Source: precisiononcologynews.com
Europe's first dual orexin receptor antagonist – QUVIVIQ
QUVIVIQ™▼ is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable...
Source: globenewswire.com
Idorsia Pharmaceuticals Ltd: Europe's first dual orexin receptor antagonist - QUVIVIQ (daridorexant) - granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder
QUVIVIQ? is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioningComprehensive nighttime
Source: finanznachrichten.de
Pfizer, Inc. (PFE) CEO Albert Bourla on Q1 2022 Results - Earnings Call Transcript
Pfizer, Inc. (NYSE:NYSE:PFE) Q1 2022 Earnings Conference Call May 03, 2022, 10:00 ET Company Participants Christopher Stevo - SVP & Chief IR Officer Albert Bourla - Chairman & CEO...
Source: seekingalpha.com
Drive sustainable Progress: The healing power of data
Digital twin technology has the potential to revolutionize medical research and identify the right treatment for each individual patient, but progress is being held up by a lack of quality data.
Personalised Medicine To Precision Public Health A European Health Data Space Open Systems Pharmacology General Data Protection Regulation European Health Data Space International Council
Source: politico.eu